TY - JOUR
T1 - Ngr-htnf plus doxorubicin in relapsed ovarian carcinoma
AU - Lorusso, Domenica
AU - Mancini, Maria
AU - Sarno, Italo
AU - Lambiase, Antonio
AU - Raspagliesi, Francesco
PY - 2012
Y1 - 2012
N2 - Ovarian cancer (OC) is the most deadly gynaecological cancer. Despite surgery and first-line chemotherapy, between 60 % and 70 % of OC patients will recur with poor prognosis. Several studies suggest anti-tumour activity of tumour necrosis factor (TNF) when given systematically, but the high toxicity of the drug has limited its use. NGR-human TNF (hTNF) consists of TNF coupled with the peptide NGR that selectively binds to CD13, which is overexpressed on tumour blood vessels. NGR-hTNF is able to increase the intratumoural doxorubicin distribution by altering tumour vasculature. The activity and toxicity profile of NGR-hTNF-doxorubicin combination in recurrent OC will be described.
AB - Ovarian cancer (OC) is the most deadly gynaecological cancer. Despite surgery and first-line chemotherapy, between 60 % and 70 % of OC patients will recur with poor prognosis. Several studies suggest anti-tumour activity of tumour necrosis factor (TNF) when given systematically, but the high toxicity of the drug has limited its use. NGR-human TNF (hTNF) consists of TNF coupled with the peptide NGR that selectively binds to CD13, which is overexpressed on tumour blood vessels. NGR-hTNF is able to increase the intratumoural doxorubicin distribution by altering tumour vasculature. The activity and toxicity profile of NGR-hTNF-doxorubicin combination in recurrent OC will be described.
KW - Doxorubicin
KW - NGR-hTNF
KW - Recurrent ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=84884269627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884269627&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84884269627
VL - 9
SP - 9
JO - European Oncology and Haematology
JF - European Oncology and Haematology
SN - 2045-5275
IS - 1
ER -